Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Vascular endothelial growth factor receptor 3 (VEGF-R3), protein kinase domain, 10 µg  

Recombinant Vascular endothelial growth factor receptor 3 (VEGF-R3), protein kinase domain, 10 µg

Recombinant human VEGF-R3 (vascular endothelial growth factor receptor 3), protein kinase domain, amino acids N799-R1298, active enzyme

Alternate names: recombinant, human, protein, VEGFR-3, Vascular permeability factor receptor, Fms-like tyrosine kinase 4, FLT4, FLT-4, VEGFR3, VEGF R3

More details

PK-VEGFR3-A010

Availability: on stock

465,00 €

Background: The vascular endothelial growth factor receptors (VEGFRs), primarily expressed in the vascular system, are members of the RTK superfamily belonging to the same subclass as receptors for PDGFs and FGFs. The receptors are equipped with an extracellular domain, which is organized into seven immunoglobulin (Ig)-like folds,followed by a single transmembrane region, a juxtamembrane domain, a split tyrosine-kinase domain interrupted by a 70-amino-acid kinase insert, and a C-terminal tail. Binding of VEGFs to the receptor leads to the formation of VEGFR homodimers and heterodimers and upon this in an activation of the receptor-kinase by autophosphorylation on multiple tyrosine residues. Phosphorylated receptors recruit interacting proteins and thus induce the activation of several signaling pathways. Upregulation of VEGF in tumor cells and its receptors (VEGFRs) on endothelial cells has been shown to contribute to tumor-associated angiogenesis. VEGFR1 is required for the recruitment of haematopoietic precursors and migration of monocytes and macrophages, whereas VEGFR2 and VEGFR3 are essential for the functions of vascular endothelial and lymphendothelial cells, respectively. Signal transduction induced by VEGFR-2 and VEGFR-3 drive angiogenesis, whereas VEGFR-1 mostly acts to restrict the angiogenic response and recruit macrophages for tissue remodeling.

Purified recombinant human Human VEGF-R3, C-terminal fragment, amino acids N799-R1298, GST-HIS6 fusion   protein with a Thrombin cleavage site, in vitro auto activation

Theoretical MW (VEGF-R3): 85.6 kDa (fusion proteins)
Expression system: Baculovirus infected Sf9 cells
Purification: One-step affinity purification using glutathione agarose
Storage buffer:     50 mM HEPES pH 7.5, 100 mM NaCl, 5 mM DTT, 15 mM reduced   
glutathione, 20% glycerol
Protein concentration: 0.151 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MSFC membrane
Specific activity: 58,000 pmol/mg min

Entrez Gene ID:2324
UniProtKB: P35916

Ordering information: shipped on dry ice

Product specific literature: 

Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L.(2006) “VEGF receptor signalling - in control of vascular function.” Nat Rev Mol Cell Biol;7(5):359-71.

Christopoulos A, Ahn SM, Klein JD, Kim S.(2011) “Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis.”Head Neck.33(8):1220-9.

Roskoski R. Jr,”VEGF receptor protein- tyrosine kinases: structure and regulation”,Biochemical and Bioohysical research communications 375 (2008), 287- 291.

 

The following products could also be interesting for you: